New Validation and Clinical Outcome Data From Several Studies Using Nanosphere's Infectious Disease Tests to be Presented at ECCMID 2014

NORTHBROOK, Ill., May 8, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new validation and clinical outcome data for select Verigene® multiplex molecular infectious disease tests will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Barcelona, Spain on 10 – 13 May 2014.

At ECCMID, three oral presentations and three posters from various U.S. and international medical facilities will demonstrate the accuracy and potential clinical utility of the Verigene Gram-Positive Blood Culture (BC-GP) (FDA-cleared; CE-IVD), Gram-Negative Blood Culture (BC-GN) (FDA-cleared; CE-IVD) and Enteric Pathogens (EP) (FDA clearance pending) Tests.

The following presentations will be made as part of the "PCR and Other Molecular Tests Directly on Blood: What is New?" session:

The following posters will be presented as part of the "Molecular Diagnostics of Bloodstream Infections—Session II":

The following poster will be presented as part of the "Molecular Diagnosis of Gastrointestinal Bacterial Infections – Poster Session III":

Nanosphere representatives will be at booth #84 in the ECCMID exhibit hall. In addition, the Company will be raising awareness of sepsis in support of Sepsis Alliance, a non-profit patient advocacy organization and founding member of the Global Sepsis Alliance.

The yearly ECCMID congress attracts approximately 10,000 participants, and offers a wide range of sessions including keynotes, symposia, poster sessions, educational workshops, meet-the-expert sessions and more.

About the Verigene® System

The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the blood, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at

CONTACT: Investors: Roger Moody, Chief Financial Officer 847-400-9021 Michael Rice, LifeSci Advisors 646-597-6979 Media: Lindsey Saxon, Director of Communications 847-400-9173 lsaxon@nanosphere.usSource:Nanosphere, Inc.